Dr Alan M Jones PhD, BSc. (Hons), PGCAP, FHEA, MRSC

Dr Alan M Jones

School of Pharmacy
Lecturer in Medicinal Chemistry

Contact details

Address
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

As a Lecturer in Medicinal Chemistry, Alan is involved in the development and delivery of the Medicinal Chemistry course that forms an integral part of the new flagship Master of Pharmacy (MPharm) undergraduate degree programme within the College of Medical and Dental Sciences.

Alan joined the University via postdoctoral appointments in cancer drug discovery at Oxford University and the Institute of Cancer Research (ICR), London and most recently an academic appointment at Manchester Met. University.

The Jones Group has active interests in developing routes to and optimising new small molecule chemical probes and ultimately drug candidates. The Jones Group Lab Webpages can be found at: www.jonesgroupresearch.wordpress.com

Qualifications

  • PhD in Chemistry (St Andrews University)
  • BSc. (Hons) in Chemistry, First Class (University of Aberdeen)

Biography

Graduating with First Class Honours in Chemistry (with a drug discovery placement at Cyclacel plc.) at the University of Aberdeen in 2005, Alan undertook doctoral training with Prof. Nick Westwood at St Andrews University, graduating with his PhD in Chemistry in 2009. Alan then began his postdoctoral career at Oxford University, in the research groups of both Professor Steve Davies and Professor Angela Russell, identifying inhibitors of both epigenetic and kinase targets. Alan then moved to the ICR, in the research group of Professor Ian Collins, to investigate the structure-based design of inhibitors of stress response proteins. In May 2014, Alan took up his first Lectureship in Pharmaceutical Chemistry at Manchester Met. University. As of January 2017, Alan holds a Lectureship in Medicinal Chemistry at the School of Pharmacy. His group has interests in new synthetic methodology applied to medicinal chemistry.

Teaching

  • Medicinal and Pharmaceutical Chemistry (Chemistry for Pharmacists: years 1 and 2)
  • MSc Drug Discovery (School of Chemistry)

Postgraduate supervision

The Jones Group currently consists of 4 PhD, 2 MChem and 2 MSc by Research students.  We are actively seeking high quality candidates (at MSc, PhD or Postdoc toral level) to join our group – details of recent research projects and publications are detailed on our Group website.

Research

We are young research group actively developing new synthetic routes to bioactive small molecules and in partnership with our extensive network of collaborators testing these compounds to elucidate biological pathways of relevance to a variety of disease states for ultimately patient benefit. To achieve these ambitious goals, we are investigating two main topics:

New Synthetic Methodology

We are developing novel and enabling electrosynthetic routes to small molecules required in the pharmaceutical and fine chemical industries to accelerate drug discovery.

Medicinal Chemistry

We are investigating the role of small molecules in a variety of disease states with research groups at Leeds, Berlin, UCL School of Pharmacy, Manchester, Salford and MMU.

Other activities

  • British Council – UK Science Research Programme on the Engineering and Physical Sciences Review Panel (Newton Fund reviewer and panel member).
  • EPSRC Associate Peer Review College Member.
  • Member of the Royal Society of Chemistry (MRSC)
  • Member of the American Chemical Society
  • Member of the Society of the Chemical Industry
  • Member of the British Society for Cardiovascular Research
  • Reviewer for the University of Sharjah, United Arab Emirates

Publications

Al-Ani AJ and Jones AM. Mechanistic Investigation of a Novel Medium-sized Ring Rearrangement. Synlett, 2018, 29, 589-592 E-first.

Gill DM, Iveson M, Collins I, Jones AM. A Mitsunobu reaction to functionalized cyclic and bicyclic N-arylamines” Tetrahedron Lett. 2018, 59, 238-242.

Barone MR and Jones AM. Selective C-H Bond Electro-oxidation of Benzylic Acetates and Alcohols to Benzaldehydes. Org. Biomol. Chem. 2017, accepted DOI: 10.1039/C7OB02300F.

Green MT, Peczkowski GP, Al-Ani AJ, Benjamin SL, Simpkins NS and Jones AM* Total Synthesis and Structural Revision of a Mangrove Alkaloid. RSC Adv. 2017, 7, 48754-48758.

Bataille CJR, Brennan MB, Byrne S, Davies SG, Durbin M, Fedorov O, Huber KVM, Jones AM, Knapp S, Liu G, Nadali A, Quevedo CE, Russell AJ, Walker RG, Westwood R and Wynne GM. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.  Bioorg. Med. Chem. 2017, 25, 2657-2665.

Mahmoud AM, Wilkinson FL, Jones AM, Wilkinson JA, Romero M, Duarte J and Alexander MY.  A novel role for small molecule glycomimetics in the protection against lipid-induced endothelial dysfunction: involvement of Akt/eNOS and Nrf2/ARE signaling BBA General Subjects 2017, 1861, 3311-3322.

Jones AM,  Westwood IM, Osborne JD, Matthews TP, Cheeseman MD, Rowlands MG, Jeganathan F, Burke R, Lee D, Kadi N, Liu M, Richards M, McAndrew C, Yahya N, Dobson SE, Jones K, Workman P, Collins I, van Montfort RLM. A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoformsSci. Rep. 2016, 6, 34701.

Jones AM, Patterson S, Lorion ML, Slawin AMZ, Westwood NJ. A Core Switching Strategy to Pyrrolo[2,3-b]quinolines and Diazocino[1,2-a]indolinones. Org. Biomol. Chem. 2016, 14, 8998-9011.

Cheeseman MD, Westwood IM, Barbeau O, Rowlands M, Dobson S, Jones AM, Jeganathan F, Burke R, Kadi N, Workman P, Collins I,  van Montfort RLM, Jones K. Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.  J. Med. Chem. 2016, 59, 4625−4636.